SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES TESTOSTERON. Generic Brand HICL GCN Exception/Other ROUTE MISCELL.

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES TESTOSTERON. Generic Brand HICL GCN Exception/Other ROUTE MISCELL."

Transcription

1 Generic Brand HICL GCN Exception/Other ANDRODERM ROUTE MISCELL. ANDROGEL AXIRON FORTESTA NATESTO STRIANT TESTIM VOGELXO DEPO ROUTE MISCELL. CYPIONATE TESTOSTERON E GCN DELATESTRYL ROUTE MISCELL. ENANTHATE METHYLTESTOSTERO NE GUIDELINES FOR USE TESTRED ANDROID METHITEST ROUTE MISCELL. 1. Is the request for a male patient with a diagnosis of primary or secondary hypogonadism (hypotestosteronism or low testosterone) who meets ONE of the following criteria? The patient has a previously approved prior authorization for testosterone or has been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history OR The patient has AT LEAST ONE of the following laboratory values confirming low testosterone levels: o Total serum testosterone level of less than 300 ng/dl (10.4 nmol/l) o Low total serum testosterone level as indicated by a lab result with a reference range obtained within the past 90 days o Free serum testosterone level of less than 5 pg/ml (0.17 nmol/l) If yes, continue to #2. If no, continue to #4. Revised: 09/29/2017 Page 1 of 13

2 GUIDELINES FOR USE (CONTINUED) 2. Is the request for Androderm, Fortesta, Natesto, Striant, Testim, Vogelxo, Testred, Android, or Methitest and has the following criteria been met? The patient has previously tried or has a contraindication to Androgel AND Axiron If yes, approve the requested agent for lifetime by GPID with the following quantity limits: Androderm (testosterone): (2mg, 2.5mg, 4mg or 5mg patches) 30 patches per 30 days. Fortesta (testosterone): up to 120 grams per 30 days (2 of the 60-gram pumps). Natesto (testosterone): up to grams (3 bottles) per 30 days. Striant (testosterone): 60 systems (tablets) per 30 days. Testim (testosterone): ([1%] 50mg per 5 gram gel tube) up to 2 tubes per day per 30 days. Vogelxo (testosterone): ([1%] 50mg per 5 gram gel tube) up to 2 tubes per day per 30 days; (50mg/5 gram gel packet) up to 2 packets per day per 30 days; (12.5mg/1.25 gram pump) up to 4 of the 75 gram pumps per 30 days. Testred (methyltestosterone): (10mg capsules) 5 capsules per day. Android (methyltestosterone): (10mg capsules) 5 capsules per day. Methitest (methyltestosterone): (10mg tablets) 5 tablets per day. If no, continue to #3. 3. Is the request for AndroGel 1%, AndroGel 1.62%, Axiron, Depo-Testosterone (testosterone cypionate), or testosterone enanthate (Delatestryl)? If yes, approve the requested agent for lifetime by GPID with the following quantity limits: AndroGel 1% (testosterone): (2.5 gram packet) up to 5 grams per day per 30 days; (5 gram packet) up to 10 grams per day per 30 days; or up to 4 of the 75 gram pumps. AndroGel 1.62% (testosterone): (1.25 gram packet) up to 1.25 grams per day per 30 days; (2.5 gram packet) up to 5 grams per day per 30 days; or up to 2 of the 75 gram pumps per 30 days. Axiron (testosterone): (30mg per pump, 60 pumps per container) up to 180mL per 30 days (2 of the 90mL metered-dose pumps). Depo-Testosterone (testosterone cypionate): (100mg/mL, 200mg/mL 10mL vial) up to 1 vial per 30 days. Depo-Testosterone (testosterone cypionate): (200mg/mL, 1mL vial) up to 10 vials per 30 days. Revised: 09/29/2017 Page 2 of 13

3 Testosterone enanthate (Delatestryl): (200mg/mL, 5mL vial) 1 vial per 30 days. If no, do not approve. DENIAL TEXT: See the denial text at the end of the guideline. Revised: 09/29/2017 Page 3 of 13

4 GUIDELINES FOR USE (CONTINUED) 4. Is the request for a male patient with a diagnosis of delayed puberty not secondary to a pathological disorder who meets ONE of the following criteria: The request is for testosterone enanthate (Delatestryl) The request is for methyltestosterone (Testred, Android, or Methitest) AND the patient had a previous trial of or contraindication to Delatestryl If yes, approve the requested agent for lifetime by GPID with the following quantity limits: Delatestryl (testosterone enanthate): (200mg/mL, 5mL vial) 1 vial per 30 days. Testred (methyltestosterone): (10mg capsules) 5 capsules per day. Android (methyltestosterone): (10mg capsules) 5 capsules per day. Methitest (methyltestosterone): (10mg tablets) 5 tablets per day. If no, continue to #5. 5. Is the request for testosterone cypionate (Depo-Testosterone) for a diagnosis of gender dysphoria and the patient is at least 18 years of age? If yes, approve the requested agent for 12 months by GPID with the following quantity limits: Testosterone cypionate (Depo-Testosterone) 100mg/mL, 200mg/mL 10mL vial: 1 vial per 30 days. Testosterone cypionate (Depo-Testosterone) 200mg/mL, 1mL vial: 10 vials per 30 days. If no, continue to #6. 6. Is the request for a female patient with a diagnosis of metastatic breast cancer who meets ONE of the following criteria? The request is for testosterone enanthate (Delatestryl) The request is for methyltestosterone (Testred, Android, or Methitest) AND the patient had a previous trial of or contraindication to Delatestryl If yes, approve for requested agent for lifetime by GPID with the following quantity limits: Delatestryl (testosterone enanthate): (200mg/mL, 5mL vial) 1 vial per 30 days. Testred (methyltestosterone): (10mg capsules) 20 capsules per day. Android (methyltestosterone): (10mg capsules) 20 capsules per day. Methitest (methyltestosterone): (10mg tablets) 20 tablets per day. If no, do not approve. DENIAL TEXT: See the denial text at the end of the guideline. Revised: 09/29/2017 Page 4 of 13

5 Revised: 09/29/2017 Page 5 of 13

6 GUIDELINES FOR USE (CONTINUED) DENIAL TEXT: The guideline named requires a diagnosis of primary or secondary male hypogonadism (hypotestosteronism or low testosterone), delayed puberty in males not secondary to a pathological disorder, gender dysphoria, or metastatic breast cancer. For a diagnosis of metastatic female breast cancer or delayed puberty in males not secondary to a pathological disorder, only testosterone enanthate (Delatestryl) or methyltestosterone (Testred, Android, or Methitest) may be approved. For patients with gender dysphoria, only testosterone cypionate (Depo-Testosterone) may be approved. In addition, the following criteria must also be met. For male patients with a diagnosis of primary or secondary hypogonadism, approval requires that the following criteria must also be met. The patient has a previously approved prior authorization for testosterone or has been receiving any form of testosterone replacement therapy as indicated per physician attestation or claims history OR The patient has AT LEAST ONE of the following laboratory values confirming low testosterone levels: o Total serum testosterone level of less than 300ng/dL (10.4 nmol/l) o Low total serum testosterone level as indicated by a lab result with a reference range obtained within 90 days o Free serum testosterone level of less than 5 pg/ml (0.17 nmol/l). For requests of Androderm, Fortesta, Natesto, Striant, Testim, Vogelxo, Testred, Android, or Methitest, approval requires that the following criteria must also be met. The patient has previously tried or has a contraindication to Androgel and Axiron For patients with a diagnosis of gender dysphoria, approval requires: The patient is at least 18 years old. For male patients requesting methyltestosterone (Testred, Android or Methitest) for a diagnosis of delayed puberty not secondary to a pathological disorder, approval requires a previous trial of or contraindication to testosterone enanthate (Delatestryl). Please note that Delatestryl requires a prior authorization. For female patients requesting methyltestosterone (Testred, Android or Methitest) for a diagnosis metastatic breast cancer, approval requires a previous trial of or contraindication to testosterone enanthate (Delatestryl). Please note that Delatestryl requires a prior authorization. Revised: 09/29/2017 Page 6 of 13

7 RATIONALE Ensure appropriate diagnostic, utilization, and safety criteria. Normal testosterone level is defined for males as between 300-1,200ng/dL per the National Institute on Aging. Low free serum testosterone level is defined as less than 50ng/L per Adult Men with Androgen Deficiency Syndrome: An Endocrine Society Clinical Practice Guideline. Coverage for gender dysphoria is medically accepted for testosterone cypionate only as indicated in MicroMedex DrugDex. MicroMedex DrugDex has a therapeutic indication of female-to-male transsexual-gender identity disorder for testosterone cypionate. Other testosterone products do not have a medically accepted indicate for gender dysphoria or gender identity disorder. Testosterone Enanthate and methyltestosterone have an FDA indication of metastatic (skeletal) mammary cancer. The other testosterone products do not have a medically accepted indication for metastatic mammary cancer. FDA APPROVED INDICATIONS ANDRODERM (testosterone transdermal system) is indicated for testosterone replacement therapy in men for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter s Syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations accompanied by gonadotropins (FSH, LH) above the normal range. Secondary, i.e., hypogonadotropic hypogonadism (congenital or acquired) - idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low serum testosterone concentrations without associated elevation in gonadotropins. ANDROGEL, an androgen, is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary Hypogonadism (Congenital or Acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic Hypogonadism (Congenital or Acquired) - idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitaryhypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum levels but have gonadotropins in the normal or low range. AXIRON, an androgen is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterones: Primary Revised: 09/29/2017 Page 7 of 13

8 hypogonadism (congenital or acquired); Hypogonadotropic hypogonadism (congenital or acquired). Not indicated in males <18 years of age. Revised: 09/29/2017 Page 8 of 13

9 FDA APPROVED INDICATIONS (CONTINUED) DEPO- INJECTION is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) - idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. DELATESTRYL (Testosterone Enanthate Injection, USP) is indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. May be used secondarily in woman with advancing inoperable metastatic (skeletal) mammary cancer who are one to five years postmenopausal. FORTESTA is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone including primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired). Important limitation of use: safety and efficacy of FORTESTA in males <18 years old have not been established. NATESTO is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) Hypogonadotropic hypogonadism (congenital or acquired) Limitations of use: safety and efficacy of Natesto in males less than 18 years old have not been established. STRIANT is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired) - idiopathic gonadotropin or LHRH deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. These patients have low serum testosterone levels but have gonadotropins in the normal or low range. Revised: 09/29/2017 Page 9 of 13

10 FDA APPROVED INDICATIONS (CONTINUED) TESTIM is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired) - idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitaryhypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum levels but have gonadotropins in the normal or low range. Testim has not been clinically evaluated in males less than 18 years of age. TESTRED, ANDROID, AND METHITEST are androgens, indicated for replacement therapy in the following patients: Males with conditions associated with a deficiency or absence of endogenous testosterone: o Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testes syndrome: or orchidectomy. o Hypogonadotropic hypogonadism (congenital or acquired) - idiopathic or gonadotropic LHRH deficiency, or pituitary- hypothalamic injury from tumors, trauma or radiation. o Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously later. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. Females: may be used secondarily in woman with advancing inoperable metastatic (skeletal) mammary cancer who are one to five years postmenopausal. VOGELXO, an androgen, indicated for replacement therapy in males for conditions in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired). Hypogonadotropic hypogonadism (congenital or acquired). Revised: 09/29/2017 Page 10 of 13

11 REFERENCES Lilly USA, LLC. Axiron Package Insert. Indianapolis, IN. July, Auxilium Pharmaceuticals, Inc. Testim package insert. Malvern, PA. September Bartor Pharmacal Co.; Inc. Testopel package insert. Rye, NY. January Columbia Laboratories, Inc. Striant package insert. Livingston, NJ. February Conway AJ, Handelsman DJ, Lording DW, Stuckey B, Zajac JD. Use, misuse and abuse of androgens. MJA. 2000; 172: Endo Pharmaceuticals. Fortesta package insert. Chadds Ford, PA. April, Francis S. Greenspan and David G. Gardner eds. Lange Basic and Clinical Endocrinology. 7th ed. McGraw-Hill Companies, Inc.; Gould DC, Petty R, Jacobs HS. The male menopause: does it exist? BMJ. 2000; 320: Endo Pharmaceuticals, Inc. Delatestryl package insert. Chadds Ford, PA. June, Lui PY, Swerdloff RS, Wang C. Relative testosterone deficiency in older men: Clinical definition and presentation. Endocrinol Metab Clin N Am. 2005; 34: Miller KK. Special Articles: Hormones and Reproductive Health. J Clin Endocrinol Metab 2001; 86(6): National Institute on Aging. Scientific task force to examine usefulness of testosterone replacement therapy in older men [online]. NIH News Release. November 6, Available at: htm [Accessed July 21, 2009]. Valeant Pharmaceuticals. Testred package insert. Aliso Viejo, CA. June 2014 Petak SM. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients-2002 Update. Endocrine Practice. 2002; 8 (6): Pharmacia & Upjohn Company. Depo-Testosterone package insert. New York, NY. September Shalender B, Glenn, Cunningham, FJ, et al. Adult Men with Androgen Deficiency Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, June 2010, 95(6): Available at: [Accessed July 25, 2011]. The Formulary Monograph Service, Facts and Comparisons, St Louis, Missouri, Abbott Laboratories. Androgel 1% package insert. North Chicago, IL. November, Abbott Laboratories. Androgel 1.62% package insert. North Chicago, IL. April, Watson Pharma, Inc. Androderm package insert. Parsippany, NJ. October Upsher-Smith Laboratories, Inc. Vogelxo Package Insert. Maple Grove, MN. June, Revised: 09/29/2017 Page 11 of 13

12 UpToDate, Inc. Testosterone treatment of male hypogonadism. UpToDate [database online]. Waltham, MA. Available at: edtitle=1%7e50&sectionrank=1&anchor=h #h1. Accessed on March 17, 2015 Revised: 09/29/2017 Page 12 of 13

13 REFERENCES (CONTINUED) Bhasin S, Cunningham GR, et al. Testosterone therapy in adult men with androgen deficiency syndromes: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, June 2010, 95(6): Trimel Pharmaceuticals Press Release: Trimel Receives FDA Approval for Natesto Nasal Gel to Treat Men with Low Testosterone. May 28, Available at: Natesto-Nasal-Gel-to-Treat-Men-with-Low-Testosterone. Accessed on March 17, 2015 Sexson E, Knezevich J. Male Hypogonadism: A Review of the Disease and Its Treatment. US Pharm. 2010; 35(6):HS7-HS16. Available at: Accessed on March 17, 2015 Dandona P, Rosenberg MT. A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract May; 64(6): Available at: Accessed on March 17, Food and Drug Administration. Background documents for the joint meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. September 17, Available at: ugs/reproductivehealthdrugsadvisorycommittee/ucm pdf. Accessed on November 4, 2014 Food and Drug Administration. Testosterone Products: Drug Safety Communication- FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke. March 3, Available at: alproducts/ucm htm. Accessed on March 17, Natesto [Prescribing Information]. Malvern, PA: Endo Pharmaceuticals Inc.; November Valeant Pharmaceuticals. Testred package insert. Bridgewater, NJ. April Commercial X Market Place X Created: 11/16 Effective : 1/1/18 Client Approval: P&T Approval: Revised: 09/29/2017 Page 13 of 13

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES Generic Brand HICL GCN Exception/Other METHYL ANDROID METHITEST METHYL TESTRED 01404 ROUTE MISCELL. CYPIONATE ENANTHATE GUIDELINES FOR USE ANDRODERM ANDROGEL AXIRON FORTESTA NATESTO STRIANT TESTIM VOGELXO

More information

Testosterone Topical/Buccal/Nasal

Testosterone Topical/Buccal/Nasal BENEFIT APPLICATION Testosterone Topical/Buccal/Nasal DRUG POLICY Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.CPA.291 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent

Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent Androgens/Anabolic Steroids Prior Authorization with Quantity Limit Through Preferred

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2018-9 Program Prior Authorization/Medical Necessity Topical Androgens Medication Axiron*, Androderm, Androgel*, Fortesta*, Natesto*,

More information

Testosterone Hormone Replacement Drug Class Prior Authorization Protocol

Testosterone Hormone Replacement Drug Class Prior Authorization Protocol Line of business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Testosterone Hormone Replacement Drug Class Prior Authorization Protocol This policy has been developed through

More information

Androgens and Anabolic Steroids Prior Authorization with Quantity Limit Through Preferred Topical Androgen Criteria Program Summary

Androgens and Anabolic Steroids Prior Authorization with Quantity Limit Through Preferred Topical Androgen Criteria Program Summary OBJECTIVE The intent of the Androgens and Anabolic Steroids Prior Authorization with Quantity Limit (PA) program is to appropriately select patients for therapy according to product labeling and/or clinical

More information

Current Data and Considerations Novel Testosterone Formulations

Current Data and Considerations Novel Testosterone Formulations Current Data and Considerations Novel Testosterone Formulations 1 Current and Novel Therapeutic Options Module 4 2 Objectives Identify desirable characteristics of ideal testosterone formulations Review

More information

Medical Policy Testosterone Therapy

Medical Policy Testosterone Therapy Medical Policy Testosterone Therapy Subject: Testosterone Therapy Effective Date: April 2015 Overview: Testosterone cypionate, testosterone enanthate, testosterone undecanoate, and testosterone pellet

More information

Comparison of Testosterone Replacement Therapy Medications in the Treatment of Hypogonadism

Comparison of Testosterone Replacement Therapy Medications in the Treatment of Hypogonadism Brigham Young University BYU ScholarsArchive All Student Publications 2016-07-27 Comparison of Testosterone Replacement Therapy Medications in the Treatment of Hypogonadism Christopher M. Williams Brigham

More information

Testosterone Replacement Therapy

Testosterone Replacement Therapy 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca info@odprn.ca Testosterone Replacement Therapy Environmental Scan and Local/Historical Context December 1, 2014 2 Executive Summary Part A: Pharmacy Benefit

More information

Case ILN/1:14-cv Document 1 Filed 04/30/14 Page 1 of 10 BEFORE THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION ) ) ) ) ) )

Case ILN/1:14-cv Document 1 Filed 04/30/14 Page 1 of 10 BEFORE THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION ) ) ) ) ) ) Case ILN/1:14-cv-02934 Document 1 Filed 04/30/14 Page 1 of 10 BEFORE THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION IN RE: ANDROGEL PRODUCTS LIABILITY LITIGATION MDL DOCKET NO. 2545 OPPOSITION OF DEFENDANTS

More information

Insight into male menopause'

Insight into male menopause' Insight into male menopause' Dr Mark Vanderpump MD FRCP Consultant Endocrinologist Clinics: Tuesday PM Mark Vanderpump Consultant Physician and Endocrinologist Introduction Serum total and free testosterone

More information

Male Hormone Replacement Therapy. Punita Dhindsa D.O PGY 2

Male Hormone Replacement Therapy. Punita Dhindsa D.O PGY 2 Male Hormone Replacement Therapy Punita Dhindsa D.O PGY 2 Physiology of Testosterone & Causes of Hypogonadism in Males The use of testosterone therapy is very common in the US, with an estimated 2.3 million

More information

NEW ZEALAND DATA SHEET

NEW ZEALAND DATA SHEET NEW ZEALAND DATA SHEET 1. PRODUCT NAME DEPO-TESTOSTERONE 100mg/mL Solution for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml solution for injection contains 100 mg/ml testosterone cypionate.

More information

pump. a metered-dose pump that delivers 30 mg of testosterone per twist. Each metered-dose pump is supplied with an applicator.

pump. a metered-dose pump that delivers 30 mg of testosterone per twist. Each metered-dose pump is supplied with an applicator. 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AXIRON safely and effectively. See full prescribing information for AXIRON. AXIRON (testosterone)

More information

PRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate)

PRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate) PRODUCT INFORMATION TESTOVIRON DEPOT (testosterone enanthate) NAME OF THE MEDICINE Testosterone enanthate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of

More information

Androgen deficiency in the aging male

Androgen deficiency in the aging male Androgen deficiency in the aging male Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society for Male Reproduction and Urology The American Society for Reproductive

More information

Pathways and manipulation of testosterone biosynthesis and metabolism

Pathways and manipulation of testosterone biosynthesis and metabolism Pathways and manipulation of testosterone biosynthesis and metabolism Dihydrotestosterone 8% Pregnenolone 3-βSD Progesterone 17- Pregnenolone 17a--lase 17-Progesterone 3-βSD 17a--lase Androstenedione DEA

More information

Testosterone for Sale

Testosterone for Sale Testosterone for Sale Testosterone (C 19 H 28 O 2 ) is the male hormone. The brain, the pituitary gland, and the testes must work in perfect harmony to produce adequate amounts of it. If you want to know

More information

TREATMENT OPTIONS FOR MALE HYPOGONADISM

TREATMENT OPTIONS FOR MALE HYPOGONADISM TREATMENT OPTIONS FOR MALE HYPOGONADISM Bruce Biundo, RPh, FACA PCCA Pharmacy Consulting Department Updated July 2012 Hypogonadism in men is primarily a state involving lower than expected levels of testosterone,

More information

ANDROGENS PLAY AN essential role in the sexual

ANDROGENS PLAY AN essential role in the sexual 0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(11):5429 5434 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2004-0897 Intramuscular Testosterone

More information

PRODUCT INFORMATION PRIMOTESTON DEPOT. (testosterone enantate)

PRODUCT INFORMATION PRIMOTESTON DEPOT. (testosterone enantate) PRODUCT INFORMATION PRIMOTESTON DEPOT (testosterone enantate) NAME OF THE MEDICINE Testosterone enantate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of testosterone

More information

Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended

Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended Andriol Testocaps, Sustanon and Testosterone Implants [] NL/W/0026/pdWS/001

More information

Package Leaflet: Information for the patient. Sustanon 250, 250 mg/ml, solution for injection (testosterone esters)

Package Leaflet: Information for the patient. Sustanon 250, 250 mg/ml, solution for injection (testosterone esters) Package Leaflet: Information for the patient Sustanon 250, 250 mg/ml, solution for injection (testosterone esters) Read all of this leaflet carefully before you start using this medicine because it contains

More information

FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM

FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM 750 West Broadway Street Suite 905 Vancouver, BC M5Z 1K1 FAX: (604) 648-9003 vancouveroffice@donovanmedical.com FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM What is finasteride? Finasteride

More information

Testosterone Use and Effects

Testosterone Use and Effects Parkland College Natural Sciences Poster Sessions Student Works 2013 Testosterone Use and Effects Brandon Mills Parkland College Recommended Citation Mills, Brandon, "Testosterone Use and Effects" (2013).

More information

Health Products Regulatory Authority

Health Products Regulatory Authority 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Myodine 25 mg/ml solution for injection for dogs and cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substance: Nandrodine laurate 25

More information

TESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc.

TESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc. GENCOR PACIFIC, INC. 920 E. Orangethorpe Avenue, Suite B, Anaheim, CA 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com gita@gencorpacific.com www.gencorpacific.com TESTOFEN

More information

PRODUCT INFORMATION PROVIRON

PRODUCT INFORMATION PROVIRON PRODUCT INFORMATION PROVIRON NAME OF TE MEDICINE Mesterolone is a white to yellowish crystalline powder and is practically insoluble in water. The chemical name for mesterolone is 17 beta-ydroxy-1 alpha-methyl-5

More information

1001 West Broadway, Vancouver, BC V6H 4B1. Topical Finasteride

1001 West Broadway, Vancouver, BC V6H 4B1. Topical Finasteride 1001 West Broadway, Vancouver, BC V6H 4B1 Topical Finasteride 1 Topical finasteride is a solution containing the drug finasteride typically sold under the brand names Propecia and Proscar. The Finasteride

More information

PRESCRIBING INFORMATION

PRESCRIBING INFORMATION PRESCRIBING INFORMATION C DELATESTRYL* testosterone enanthate Solution for Injection, 200 mg/ml Androgens Valeant Canada LP 2150 Blvd. St-Elzear West Laval, Quebec H7L 4A8 Date of Revision: August 19,

More information

HGH for Sale Human Growth Hormone

HGH for Sale Human Growth Hormone HGH for Sale Human Growth Hormone Many people consider HGH for sale, or Human Growth Hormone (C 990 H 1529 N 263 O 299 S 7 ) the fountain of youth. In fact, many experts suggest that this is the most sought-after

More information

TEV-TROPIN [somatropin (rdna origin) for injection] 5 mg & 10 mg

TEV-TROPIN [somatropin (rdna origin) for injection] 5 mg & 10 mg TEV-TROPIN [somatropin (rdna origin) for injection] 5 mg & 10 mg TEV-TROPIN (somatropin for injection) Information for the Patient or Parent Read all instructions before proceeding. Do not mix (reconstitute)

More information

Dextromethorphan Overutilization

Dextromethorphan Overutilization Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs Requiring PA: the list of drugs requiring prior authorization for this

More information

RECONSTITUTION AND ADMINISTRATION INSTRUCTIONS FOR HEALTHCARE PROFESSIONALS

RECONSTITUTION AND ADMINISTRATION INSTRUCTIONS FOR HEALTHCARE PROFESSIONALS RECONSTITUTION AND ADMINISTRATION INSTRUCTIONS FOR HEALTHCARE PROFESSIONALS TRUST THE POWER OF PREVENTION WITH CINRYZE Whether your patients are new to treatment or are continuing their journey, remind

More information

4.2 Posology, method and duration of administration

4.2 Posology, method and duration of administration The format of this leaflet was determined by the Ministry of Health and its content was checked and approved by it in May 2011. 1. NAME OF MEDICINAL PRODUCT Testoviron Depot Oily solution for injection

More information

DUPROST Capsules (Dutasteride)

DUPROST Capsules (Dutasteride) Published on: 10 Jul 2014 DUPROST Capsules (Dutasteride) Composition Each soft gelatin capsule contains: Dutasteride... 0.5 mg Dosage Form Capsule Pharmacology Pharmacodynamics Mechanism of Action Dutasteride

More information

Andropause How Relevant?

Andropause How Relevant? Andropause How Relevant? 323 55 Andropause How Relevant? VN MISHRA, NALINI MISHRA INTRODUCTION In day-to-day practice it is not unusual to encounter male patients in their 50s or older who come to physician

More information

Pharmacology of testosterone preparations

Pharmacology of testosterone preparations 14 Pharmacology of testosterone preparations H.M. Behre, C. Wang, D.J. Handelsman and E. Nieschlag Contents 14.1 Historical development of testosterone therapy 14.2 General considerations 14.3 Pharmacology

More information

HGH for Sale Natural Anti-Aging Human Growth Hormone

HGH for Sale Natural Anti-Aging Human Growth Hormone HGH for Sale Natural Anti-Aging Human Growth Hormone Human growth hormone is one of the hottest supplement trends on the market, and now you can purchase top-quality HGH to be delivered right to your home!

More information

Castration resistant prostate cancer-what is it? and what do we do about it? Urology Postgraduate Course February 13, 2009

Castration resistant prostate cancer-what is it? and what do we do about it? Urology Postgraduate Course February 13, 2009 Castration resistant prostate cancer-what is it? and what do we do about it? Urology Postgraduate Course February 13, 2009 Charles J Ryan, MD Associate Professor of Clinical Medicine Helen Diller Family

More information

Maturitas 67 (2010) Contents lists available at ScienceDirect. Maturitas. journal homepage:

Maturitas 67 (2010) Contents lists available at ScienceDirect. Maturitas. journal homepage: Maturitas 67 (2010) 39 45 Contents lists available at ScienceDirect Maturitas journal homepage: www.elsevier.com/locate/maturitas Review Androgen deficiency in women; role of accurate testosterone measurements

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET MATERIAL SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY Material Manufacturer Distributor Ethambutol Hydrochloride Tablets USP 100 mg and 400 mg Lupin Limited Mumbai 400 098 INDIA

More information

Anavar For Sale Oxandrolone

Anavar For Sale Oxandrolone Anavar For Sale Oxandrolone Anavar (oxandrolone C 19 H 30 O 3 ) is an anabolic steroid that provides outstanding results. The Anavar steroid is a synthesized version of testosterone that boosts lean muscle

More information

FINASTERIDE PER ALOPECIA ANDROGENETICA FEMMINILE

FINASTERIDE PER ALOPECIA ANDROGENETICA FEMMINILE FINASTERIDE PER ALOPECIA ANDROGENETICA FEMMINILE ### 1 finasteride and depression Should finasteride be taken in am or pm, finasteride 5mg tab bald blog post ideas efectos. 2 Finasteride testosterone replacement

More information

Enhanced Linear Growth Responses in Hypopituitary Dwarfs Treated with Growth Hormone Plus Androgen versus Growth Hormone Alone

Enhanced Linear Growth Responses in Hypopituitary Dwarfs Treated with Growth Hormone Plus Androgen versus Growth Hormone Alone Pediat. Res. 8: 103-108 (1974) Androgen growth hormone fluoxymesterone hypopituitary dwarfs Enhanced Linear Growth Responses in Hypopituitary Dwarfs Treated with Growth Hormone Plus Androgen versus Growth

More information

NATESTO Testosterone nasal gel 4.5% w/w

NATESTO Testosterone nasal gel 4.5% w/w PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION NATESTO Testosterone nasal gel 4.5% w/w Androgens Acerus Pharmaceuticals SRL Durants, Business Centre, Suite B Durants, Christ Church Barbados,

More information

PREPARATION AND SELF-ADMINISTRATION INSTRUCTIONS FOR PATIENTS

PREPARATION AND SELF-ADMINISTRATION INSTRUCTIONS FOR PATIENTS PREPARATION AND SELF-ADMINISTRATION INSTRUCTIONS FOR PATIENTS Hereditary Angioedema Jenny, a real HAE patient TAKE CONTROL OF YOUR HEREDITARY ANGIOEDEMA (HAE) TREATMENT WITH SELF-ADMINISTRATION Choosing

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 June 2012

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 June 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 June 2012 CINRYZE 500 units, 2100 IU, powder and solvent for solution for injection B/2 bottles (CIP code: 218

More information

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice Provider Bulletin December 2017 Quarterly pharmacy formulary notice The formulary s listed in the table below apply to all Anthem HealthKeepers Plus members. These s were reviewed and approved at the third

More information

ANDROGENIC STEROIDS such as T and its derivatives

ANDROGENIC STEROIDS such as T and its derivatives 0013-7227/01/$03.00/0 The Journal of Clinical Endocrinology & Metabolism 86(11):5108 5117 Printed in U.S.A. Copyright 2001 by The Endocrine Society CLINICAL REVIEW 138 Anabolic-Androgenic Steroid Therapy

More information

CHAPTER 10 Reconstitution of Powdered Drugs

CHAPTER 10 Reconstitution of Powdered Drugs CHAPTER 10 RECONSTITUTION OF POWDERED DRUGS 89 CHAPTER 10 Reconstitution of Powdered Drugs Objectives The learner will: 1. prepare solutions from powdered drugs using directions printed on vial labels.

More information

Evaluate the evidence for and against the use of testosterone to extend lifespan

Evaluate the evidence for and against the use of testosterone to extend lifespan 1 Evaluate the evidence for and against the use of testosterone to extend lifespan Background and introduction Testosterone is a steroid hormone which was first isolated in 1935 (David, Dingemanse, Freud

More information

IVIG Educational Presentation

IVIG Educational Presentation IVIG Educational Presentation Administration of IVIG direct from the Bottle Note: This is not the procedure please refer to the procedure in epops 16/06/2017 IVIG Administion from a bottle 1 Change in

More information

WEIGHT LOSS DURING THE

WEIGHT LOSS DURING THE ORIGINAL CONTRIBUTION Testosterone Replacement and Resistance in HIV-Infected Men With Weight Loss and Low Testosterone Levels Shalender Bhasin, MD Thomas W. Storer, PhD Marjan Javanbakht, MPH Nancy Berman,

More information

Hydrofluoric Acid SOP

Hydrofluoric Acid SOP Introduction Hydrofluoric acid (HF) has a number of chemical, physical, and toxicological properties, which make handling this material especially hazardous. Anhydrous HF is a clear, colorless, fuming,

More information

The New England Journal of Medicine

The New England Journal of Medicine The New England Journal of Medicine Copyright, 1996, by the Massachusetts Medical Society VOLUME 335 J ULY 4, 1996 NUMBER 1 THE EFFECTS OF SUPRAPHYSIOLOGIC DOSES OF TESTOSTERONE ON MUSCLE SIZE AND STRENGTH

More information

SIMPLE, EFFICIENT AND SIMULTANEOUS DETERMINATION OF ANABOLIC STEROIDS IN HUMAN URINE

SIMPLE, EFFICIENT AND SIMULTANEOUS DETERMINATION OF ANABOLIC STEROIDS IN HUMAN URINE SIMPLE, EFFICIENT AND SIMULTANEOUS DETERMINATION OF ANABOLIC STEROIDS IN HUMAN URINE Pages with reference to book, From 216 To 218 S.J. Khurshid, M. Riaz, S. Ahmed ( Nuclear Chemistry Division, Pakistan

More information

By Christopher Suprun Jr., NREMT-P, CCEMT-P

By Christopher Suprun Jr., NREMT-P, CCEMT-P By Christopher Suprun Jr., NREMT-P, CCEMT-P PHOTO FOR ILLUSTRATION ONLY. 34 Texas EMS Magazine March/April 2005 Pumped up Watching for signs of steroid use It s a quiet Saturday morning as your crew considers

More information

Product Monograph. Sandoz Dutasteride

Product Monograph. Sandoz Dutasteride Product Monograph Pr Sandoz Dutasteride Dutasteride Capsules of 0.5 mg Type I and II 5 Alpha-reductase Inhibitor Sandoz Canada Inc. 145 Jules-Léger Boucherville, QC, Canada J4B 7K8 Date of Preparation:

More information

The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia

The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia ORIGINAL ARTICLE (27) 1, 149 154 & 27 Nature Publishing Group All rights reserved 1365-7852/7 $3. www.nature.com/pcan The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men

More information

A few good women (and a large crowd of men) Results from the SMS research project

A few good women (and a large crowd of men) Results from the SMS research project A few good women (and a large crowd of men) Results from the SMS research project Kjartan Ólafsson UNIVERSITY OF AKUREYRI RESEARCH INSTITUTE Overview of the presentation The study design Data and methods

More information

Dextromethorphan Overutilization

Dextromethorphan Overutilization Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs Requiring PA: the list of drugs requiring prior authorization for this

More information

Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men

Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men Joel S. Finkelstein, M.D., Hang Lee, Ph.D., Sherri-Ann

More information

SmarterLights. Guidelines for Use. HPLED Powerheads. By Light Therapy Options, L.L.C. The Dual Care TM. The Pure Amber. The TriPeak TM.

SmarterLights. Guidelines for Use. HPLED Powerheads. By Light Therapy Options, L.L.C. The Dual Care TM. The Pure Amber. The TriPeak TM. SmarterLights HPLED Powerheads By Light Therapy Options, L.L.C. The TriPeak TM The Peak The Pure 415 TM Blue The Pure Green The Pure Amber The Dual Care TM The Pure Red Guidelines for Use 1 Quick Start

More information

Deca Durabolin. (Nandrolone Decanoate) Deca Durabolin Functions & Traits:

Deca Durabolin. (Nandrolone Decanoate) Deca Durabolin Functions & Traits: Deca Durabolin (Nandrolone Decanoate) Deca Durabolin is an extremely popular anabolic steroid comprised of the steroidal hormone Nandrolone and is attached to the large Decanoate ester. The Nandrolone

More information

26-G Keewaydin Drive, Salem, NH P: (800) F: (603)

26-G Keewaydin Drive, Salem, NH P: (800) F: (603) Dihydrotestosterone ELISA For the quantitative determination of DHT in serum. For Research Use Only. Not for Use in Diagnostic Procedures. Catalog Number: 11-DHTHU-E01 Size: 96 wells Version: 4.1 August

More information

WADA Technical Document TD2018MRPL

WADA Technical Document TD2018MRPL MINIMUM REQUIRED PERFORMANCE LEVELS FOR DETECTION AND IDENTIFICATION OF NON-THRESHOLD SUBSTANCES In order to ensure that all WADA-accredited Laboratories can report the presence of Prohibited Substances,

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET MATERIAL SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY Material Manufacturer Distributor Norethindrone Tablets USP 0.35 mg Lupin Limited Pithampur (M.P.) 454 775 INDIA Lupin Pharmaceuticals,

More information

Hospital Admissions in the Northern Territory

Hospital Admissions in the Northern Territory Hospital Admissions in the Northern Territory 1976-28 www.healthynt.nt.gov.au Hospital Admissions in the Northern Territory, 1976 to 28 Shu Qin Li Sabine Pircher Steve Guthridge John Condon Jo Wright Acknowledgements

More information

Reference guide for individual patient education

Reference guide for individual patient education Reference guide for individual patient education Integrating Long-Term Home Oxygen Therapy into the COPD patients life Topics: 1. Long-Term home oxygen therapy and oxygen equipment To have a better understanding

More information

PRE-CALCULATED PREMIUMS FOR

PRE-CALCULATED PREMIUMS FOR United Home life Insurance Company United Farm Family Life Insurance Company P.O. Box 7192 Indianapolis, Indiana 46207-7192 800-428-3001 PRE-CALCULATED PREMIUMS FOR EXPRESS ISSUE PREMIER WHOLE LIFE EXPRESS

More information

X/00/$03.00/0 Vol. 85, No. 8 The Journal of Clinical Endocrinology & Metabolism. Printed in U.S.A. Copyright 2000 by The Endocrine Society

X/00/$03.00/0 Vol. 85, No. 8 The Journal of Clinical Endocrinology & Metabolism. Printed in U.S.A. Copyright 2000 by The Endocrine Society 0021-972X/00/$03.00/0 Vol. 85, No. 8 The Journal of Clinical Endocrinology & Metabolism rinted in U.S.A. Copyright 2000 by The Endocrine Society Effects of Testosterone Replacement in Hypogonadal Men*

More information

OHRP Guidance on Written IRB Procedures

OHRP Guidance on Written IRB Procedures Office for Human Research Protections (OHRP) Department of Health and Human Services Date: OHRP Guidance on Written IRB Procedures Scope: This document outlines the required elements of written Institutional

More information

F Hodgeslz first demonstrated the marked

F Hodgeslz first demonstrated the marked STEROID RESPONSE TO THERAPY IN PROSTATIC CANCER FKEDERICK B. BURT, hl.d.,"t ROY P. FINNEY, AND WILLIAM WALLACE SCOTT, M.D. M.D.," IFTEEN years have passed since Huggins and F Hodgeslz first demonstrated

More information

1 Identification of the substance / preparation and of the company / undertaking 1.1 Product Identification Trade name: Synonyms

1 Identification of the substance / preparation and of the company / undertaking 1.1 Product Identification Trade name: Synonyms Issued date: 01/December/ 2010 Document: SDS-DT-01-02 Page 1 of 5 1 Identification of the substance / preparation and of the company / undertaking 1.1 Product Identification Trade name: Synonyms Gonadotrophin,

More information

Risks Versus Benefits of Testosterone Therapy in Elderly Men

Risks Versus Benefits of Testosterone Therapy in Elderly Men REVIEW ARTICLE Drugs & Aging 1999 Aug; 15 (2): 131-142 1170-229X/99/0008-0131/$06.00/0 Adis International Limited. All rights reserved. Risks Versus Benefits of Testosterone Therapy in Elderly Men Shehzad

More information

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

2. QUALITATIVE AND QUANTITATIVE COMPOSITION AVODART SOFT CAPSULES 0.5 MG 1. NAME OF THE MEDICINAL PRODUCT AVODART 0.5 mg capsules, soft. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 0.5 mg dutasteride. For excipients, see 6.1.

More information

Laboratory Standard Operating Procedure: Carcinogens

Laboratory Standard Operating Procedure: Carcinogens I. THIS STANDARD OPERATING PROCEDURE (SOP) IS FOR A: Specific laboratory procedure or experiment Examples: synthesis of chemiluminescent esters, folate functionalization of polymeric micelles, etc. Generic

More information

The Application of QuEChERS in the Extraction of Anabolic Steroids in Whole Blood

The Application of QuEChERS in the Extraction of Anabolic Steroids in Whole Blood The Application of QuEChERS in the Extraction of Anabolic Steroids in Whole Blood UCT Part Numbers: ECQUUS1015CT- Enviro-Clean 15 ml centrifuge tube with 400 mg MgSO 4 and 100 mg NaCl CUMPS2CT - Enviro-Clean

More information

Comparison of 7 Published LC-MS/MS Methods for the Simultaneous Measurement of Testosterone, androstenedione, and dehydroepiandrosterone.

Comparison of 7 Published LC-MS/MS Methods for the Simultaneous Measurement of Testosterone, androstenedione, and dehydroepiandrosterone. Papers in Press. Published October 26, 2015 as doi:10.1373/clinchem.2015.242859 The latest version is at http://hwmaint.clinchem.org/cgi/doi/10.1373/clinchem.2015.242859 Clinical Chemistry 61:12 000 000

More information

FULL PRESCRIBING INFORMATION

FULL PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AVODART safely and effectively. See full prescribing information for AVODART. AVODART (dutasteride)

More information

Anabolic Steroids And Other Performance Enhancing Drugs. Amy Prior-Harding University High School

Anabolic Steroids And Other Performance Enhancing Drugs. Amy Prior-Harding University High School Anabolic Steroids And Other Performance Enhancing Drugs Warm Up http://www.youtube.com/watch?v=2lgiy1nfhkm! ESSENTIAL STANDARD/OBJECTIVE:9.ATOD.1.1- Explain the short-term & long term effects of performance-enhancing

More information

Diabetes and Recreational Diving

Diabetes and Recreational Diving Guidelines for Diabetes and Recreational Diving Proceedings Summary DAN/UHMS Diabetes and Recreational Diving Workshop 1 Proceedings Summary DAN/UHMS Diabetes and Recreational Diving Workshop DAN.org Introduction

More information

Boston University School of Public Health, Boston, Massachusetts; and 2 Charles R. Drew University of Medicine and Science, Los Angeles, California

Boston University School of Public Health, Boston, Massachusetts; and 2 Charles R. Drew University of Medicine and Science, Los Angeles, California Am J Physiol Endocrinol Metab 294: E1135 E1143, 2008. First published April 22, 2008; doi:10.1152/ajpendo.90213.2008. Effects of a supraphysiological dose of testosterone on physical function, muscle performance,

More information

Introduction to the Doping Problem

Introduction to the Doping Problem Introduction to the Doping Problem Jordi Segura Director, WADA Accredited Antidoping Laboratory, IMIM-Hospital del Mar, Barcelona, Spain Doping and Society: towards the perfect human machine? ESOF, Barcelona

More information

NCCP position paper on the use of Tall Man Lettering

NCCP position paper on the use of Tall Man Lettering NCCP position paper on the use of Tall Man Lettering Version Date published Amendment Approved By 1 August 2017 Version 1 NCCP All comments and feedback are welcome at oncologydrugs@cancercontrol.ie 2

More information

Presidential address of the American Orthopaedic Society for Sports Medicine Drug abuse in sports*

Presidential address of the American Orthopaedic Society for Sports Medicine Drug abuse in sports* Presidential address of the American Orthopaedic Society for Sports Medicine Drug abuse in sports* JAY S. COX, MD President, AOSSM The reasons that athletes use drugs are to improve performance, to play

More information

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING. : ASTRAZENECA P.O. Box Wilmington, DE USA

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING. : ASTRAZENECA P.O. Box Wilmington, DE USA SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING Product identifier ZOLADEX FOR DEPOT/IMPLANT Details of the supplier of the safety data sheet : ASTRAZENECA P.O.

More information

Ankle Dorsiflexion Assist Systems

Ankle Dorsiflexion Assist Systems DORSIFLEXION ASSIST SYSTEM: REIMBURSEMENT GUIDE Available in Three Configurations Ankle Dorsiflexion Assist Systems Gait Trainer System* (see following page for coding specifics) Sleeping System Combination

More information

OXYGEN THERAPY AND QUALITY OF LIFE Oxygen Therapy and Quality of Life

OXYGEN THERAPY AND QUALITY OF LIFE Oxygen Therapy and Quality of Life OXYGEN THERAPY AND QUALITY OF LIFE Oxygen Therapy and Quality of Life Some patients with idiopathic pulmonary fibrosis (IPF) may be prescribed oxygen therapy after being assessed by a doctor. For those

More information

Hair Testing to provide additional evidence in doping cases of potential (clenbuterol) contaminations

Hair Testing to provide additional evidence in doping cases of potential (clenbuterol) contaminations Hair Testing to provide additional evidence in doping cases of potential (clenbuterol) contaminations Detlef Thieme Institute of Doping Analysis, Dresden, Germany Beijing, Oct 2017 [M. Jahn (www.kreischa.net)]

More information

Homepage: Online-Datenbank mit Autoren- und Stichwortsuche

Homepage: Online-Datenbank mit Autoren- und Stichwortsuche Testosterone replacement therapy - testosterone undecanoate (Andriol) Geurts TBP, Coelingh Bennink HJT Journal für Urologie und Urogynäkologie 2000; 7 (Sonderheft 1) (Ausgabe für Schweiz) Homepage: www.kup.at/urologie

More information

Section 1: Identification

Section 1: Identification SAFETY DATA SHEET Section 1: Identification Section 1, Identification GHS Product identifier Trade Name Rosuvastatin calcium Tablets, 5 mg, 10 mg, 20mg and 40mg Other means of identification Synonyms Rosuvastatin

More information

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

2. QUALITATIVE AND QUANTITATIVE COMPOSITION AVODART SOFT CAPSULES 0.5 MG 1. NAME OF THE MEDICINAL PRODUCT Avodart 0.5 mg capsules, soft. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 0.5 mg dutasteride. For excipients, see 6.1.

More information

OCREVUS Vials 300 mg/10 ml

OCREVUS Vials 300 mg/10 ml Safety Data Sheet OCREVUS Vials 300 mg/10 ml SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1. Product identifier Product name Product code OCREVUS Vials 300 mg/10

More information

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: 11/2017

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: 11/2017 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JALYN safely and effectively. See full prescribing information for JALYN. JALYN (dutasteride and

More information